Seller record · Telehealth service

Henry Meds

By Peptide Alliance, Editorial publisherRecorded August 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: The medications are said to be compounded in a 503(A) Compounding Pharmacy or 503(B) Outsourcing Facility, and no facility is named. 1 more criterion also fails; see the table below.

At a glance

Henry MedsTelehealth service

6/8criteria passed

Price: Semaglutide $297 a month
Sells: compounded semaglutide, compounded tirzepatide, phentermine, and 3 more
FDA letters: None on file

Visit Henry Meds See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded GLP-1 drugs, hormone therapy and sexual health medications. It publishes a program price list and names no filling pharmacy.

Operating entity Adonis Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Henry Meds' FAQ; Henry Meds' terms of service page
S2	Prescription gating	PASS	Henry Meds' weight goal page on its onboard storefront
S3	Pharmacy identification	FAIL	Henry Meds' GLP-1 weight management product page
S4	Compounding disclosure	PASS	Henry Meds' semaglutide product page
S5	Analytical documentation	FAIL	Henry Meds' sitemap page
S6	Business address	PASS	Henry Meds' terms of service page
S7	Price disclosure	PASS	Henry Meds' programs page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed healthcare provider reviews the information and recommends treatment if necessary; the clinical services come from a contracted medical group that is not named.Source: Henry Meds' FAQ; Henry Meds' terms of service page.

S2PASSThe first intake question, which asks the buyer's weight loss goal, stops the order.Source: Henry Meds' weight goal page on its onboard storefront.

S3FAILThe medications are said to be compounded in a 503(A) Compounding Pharmacy or 503(B) Outsourcing Facility, and no facility is named.Source: Henry Meds' GLP-1 weight management product page.

S4PASSCompounded medications do not undergo pre-market review or an FDA-approval process, printed in the body of the semaglutide treatment page.Source: Henry Meds' semaglutide product page.

S5FAILNo certificate, lot report or test document appears on the treatment pages, the FAQ, the terms, or anywhere else on the site.Source: Henry Meds' sitemap page.

S6PASSAdonis Health, Inc. at 1111B S Governors Ave, STE 25428, Dover, DE 19904, printed in the terms; the contact page carries only an email address and a telephone number.Source: Henry Meds' terms of service page.

S7PASSWeekly or biweekly semaglutide injections are printed at 297 dollars per month, and at 1,782 dollars for 6 months as a one-time payment.Source: Henry Meds' programs page.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, phentermine, testosterone therapy, hormone replacement therapy, sexual health medications.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Henry Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.